A secreted PD-L1 splice variant that covalently dimerizes and mediates immunosuppression

Genetic, transcriptional and post-translational regulation of the programmed death protein ligand 1 in cancer: biology and clinical correlations

(2018) Ioannis Zerdes et al.   ONCOGENE

Regulation of PD-L1: Emerging Routes for Targeting Tumor Immune Evasion

(2018) Yiting Wang et al.   Frontiers in Pharmacology

PD-L1 on tumor cells is sufficient for immune evasion in immunogenic tumors and inhibits CD8 T cell cytotoxicity

(2017) Vikram R. Juneja et al.   JOURNAL OF EXPERIMENTAL MEDICINE

High plasma levels of soluble programmed cell death ligand 1 are prognostic for reduced survival in advanced lung cancer

(2017) Yusuke Okuma et al.   LUNG CANCER

sPD-L1 Expression is Associated with Immunosuppression and Infectious Complications in Patients with Acute Pancreatitis

(2017) Y. Chen et al.   SCANDINAVIAN JOURNAL OF IMMUNOLOGY

High-affinity human PD-L1 variants attenuate the suppression of T cell activation

(2017) Zhaoduan Liang et al.   Oncotarget

Soluble PD-L1 as a Biomarker in Malignant Melanoma Treated with Checkpoint Blockade

(2017) Jun Zhou et al.   Cancer Immunology Research

Serum levels of soluble programmed death protein 1 (sPD-1) and soluble programmed death ligand 1 (sPD-L1) in advanced pancreatic cancer

(2017) Stephan Kruger et al.   OncoImmunology

Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma

(2016) Willy Hugo et al.   CELL

High levels of the soluble programmed death-ligand (sPD-L1) identify hepatocellular carcinoma patients with a poor prognosis

(2016) Fabian Finkelmeier et al.   EUROPEAN JOURNAL OF CANCER

Aberrant PD-L1 expression through 3′-UTR disruption in multiple cancers

(2016) Keisuke Kataoka et al.   NATURE

Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer

(2016) Martin Reck et al.   NEW ENGLAND JOURNAL OF MEDICINE

Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma

(2015) Robert J. Motzer et al.   NEW ENGLAND JOURNAL OF MEDICINE

Genomic correlates of response to CTLA-4 blockade in metastatic melanoma

(2015) E. M. Van Allen et al.   SCIENCE

PD-1 alters T-cell metabolic reprogramming by inhibiting glycolysis and promoting lipolysis and fatty acid oxidation

(2015) Nikolaos Patsoukis et al.   Nature Communications

PD-L1 Antibodies to Its Cytoplasmic Domain Most Clearly Delineate Cell Membranes in Immunohistochemical Staining of Tumor Cells

(2015) K. M. Mahoney et al.   Cancer Immunology Research

EBV-driven LMP1 and IFN-γ up-regulate PD-L1 in nasopharyngeal carcinoma: Implications for oncotargeted therapy

(2015) Wenfeng Fang et al.   Oncotarget

High level of soluble programmed cell death ligand 1 in blood impacts overall survival in aggressive diffuse large B-Cell lymphoma: results from a French multicenter clinical trial

(2014) D Rossille et al.   LEUKEMIA

PD-L1 Expression Is Characteristic of a Subset of Aggressive B-cell Lymphomas and Virus-Associated Malignancies

(2013) B. J. Chen et al.   CLINICAL CANCER RESEARCH

Colocalization of Inflammatory Response with B7-H1 Expression in Human Melanocytic Lesions Supports an Adaptive Resistance Mechanism of Immune Escape

(2012) J. M. Taube et al.   Science Translational Medicine

Identification of a Soluble Form of B7-H1 That Retains Immunosuppressive Activity and Is Associated with Aggressive Renal Cell Carcinoma

(2011) X. Frigola et al.   CLINICAL CANCER RESEARCH

Development of a sandwich ELISA for evaluating soluble PD-L1 (CD274) in human sera of different ages as well as supernatants of PD-L1+ cell lines

(2011) Yongjing Chen et al.   CYTOKINE

Soluble B7-H1: Differences in production between dendritic cells and T cells

(2011) Xavier Frigola et al.   IMMUNOLOGY LETTERS

Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma

(2010) M. R. Green et al.   BLOOD